---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-021869"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:30:08.720280+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics' ralinepag phase 3 meets primary endpoint; 55% risk reduction in PAH clinical worsening

## Summary
- Ralinepag reduced risk of clinical worsening by 55% vs placebo (HR 0.45, p<0.0001) in phase 3 ADVANCE OUTCOMES study.
- Statistically significant improvements in 6MWD, NT-proBNP, and 47% increased odds of clinical improvement at Week 28.
- 80% of patients on dual background therapy; safety consistent with prostacyclin class; no new signals.
- Company plans to submit NDA to FDA by second half of 2026.
- Full results to be presented at upcoming international conference.

## SEC filing metadata
- accession: 0001104659-26-021869
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465926021869/0001104659-26-021869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465926021869/tm267696d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-021869
- JSON: https://secwatch.observer/filing/0001104659-26-021869.json
- Plain text: https://secwatch.observer/filing/0001104659-26-021869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.